BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Biopharma Update on the Novel Coronavirus: September 14

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.

  September 14, 2020

   · 

  3 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Merck and Seattle Genetics Ink Two New Strategic Cancer Collaborations

  Merck is making a major investment into Bothwell, Washington-based Seattle Genetics with two strategic oncology deals.

  September 14, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  Pfizer, BioNTech Say COVID-19 Vaccine Might Be Ready by End of October

  In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.

  September 14, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  President Trump Signs New Executive Order on Prescription Drug Prices

  President Donald Trump expanded the number of drugs covered under a “favored nations clause” by Medicare Part D and Medicare Part D with a new Executive Order intended to lower the cost of prescription drugs in the United States announced Sunday.

  September 14, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Attralus Eyes Further Work on Therapeutic Candidates with New Funding

  California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round.

  September 14, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  With U.S.-China Relations Tremulous, Is China Still a Good Place to Do Business?

  When biotech companies consider conducting business in China, their concerns are radically different than they were even four years ago.

  September 14, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Deals

  Grail Files for IPO Ahead of Launching Multi-Cancer Liquid Biopsy Screening Test

  Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC).

  September 14, 2020

   · 

  2 min read

   · 

  Brandon May
• 

  Drug Development

  AstraZeneca Resumes U.K. Portion of COVID-19 Vaccine Study Following Safety Review

  AstraZeneca resumed its vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

  September 14, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Gilead Moves Deeper into Oncology with $21 Billion Acquisition of Immunomedics

  The deal, announced Sunday, has been unanimously approved by the boards of directors of both companies.

  September 14, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Strand Therapeutics’ mRNA Logic Circuits Enhance Gene Therapy’s Safety, Ease and Controllability

  The company is genetically programming RNA not just to deliver a gene of interest, but to control the location, timing and intensity of therapeutic protein expression using mRNA-encoded logic circuits.

  September 14, 2020

   · 

  4 min read

   · 

  Gail Dutton